Navigation Links
Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues

MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that in a recently completed animal study, a DNA vaccine formulated with the company's patented Vaxfectin(TM) adjuvant and delivered by needle-free injection yielded significantly higher antibody responses than an unformulated DNA vaccine delivered by needle and syringe. In a separate animal study, electroporation following injection of unformulated vaccine yielded comparable improvements in antibody responses, but electroporation required anesthesia of the animals while needle-free injection of Vaxfectin(TM)-formulated vaccine was administered safely and tolerably without anesthesia.

"The dose-sparing and immunogenicity-enhancing capabilities of the Vaxfectin(TM) adjuvant have been demonstrated in a range of vaccine applications in various animal models," said Alain P. Rolland, Pharm.D., Ph.D., Vical's Senior Vice President of Product Development, "but the potential safety and tolerability advantages of Vaxfectin(TM) compared with alternative DNA delivery enhancement options are making it our preferred choice for new development projects. We look forward to beginning the initial human testing of a Vaxfectin(TM)-formulated DNA vaccine for pandemic influenza, anticipated in the second half of 2007, and to continued exploration of Vaxfectin(TM)'s use in optimizing efficacy and safety for future prophylactic or therapeutic applications."

Both studies were conducted in rabbits with DNA vaccines encoding cytomegalovirus (CMV) glycoprotein B (gB). The vaccines were either unformulated -- using standard phosphate-buffered saline (PBS) -- or formulated -- using the company's Vaxfectin(TM) adjuvant in PBS. Vaxfectin(TM)-formulated vaccines were injected with a needle-free device. Unformulated vaccines were injected with needle and syringe followed in some animals by electroporation using either a constant voltage multi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
2. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
3. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
6. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
7. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
8. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
9. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
Post Your Comments:
(Date:9/2/2014)... ResMed (NYSE: RMD ) has introduced ... the United States . The Astral platform ... life support ventilators. ResMed,s new Astral ... use for patients suffering from neuromuscular disease, chronic obstructive ... disorders. The U.S. launch comes on the heels of ...
(Date:9/2/2014)... 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ... Administration (FDA) has granted orphan drug status to APD811 ... "The FDA Office of Orphan Products Development (OOPD) ... identify and designate drug candidates that could potentially treat ... of such products," said Craig M. Audet , ...
(Date:9/2/2014)... 2014   Intrexon Corporation (NYSE: ... that it has entered into an Exclusive Channel Collaboration ... Sanofi (EURONEXT: SAN and NYSE: SNY ) ... family of its marketed Active Pharmaceutical Ingredients (APIs) through ... . This collaboration will leverage Intrexon,s proprietary technology suite ...
Breaking Medicine Technology:ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 2ResMed's Revolutionary Life Support Ventilation Platform -- Astral 100 and 150 Devices Now Available in the U.S. 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 2Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 3Arena Pharmaceuticals' APD811 Granted Orphan Drug Status for Pulmonary Arterial Hypertension 4Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 2Intrexon Announces Exclusive Channel Collaboration with Sanofi to Optimize Production for a Specific Family of Active Pharmaceutical Ingredients 3
(Date:9/2/2014)... Humility of Mary Health Partners will offer a ... Health Center, 1044 Belmont Ave. , The workshop includes an ... common health problems as well as tips on caring for ... on when to seek medical attention. , The morning ... Room; the evening session runs from 5:30 to 6:30 p.m. ...
(Date:9/2/2014)... 02, 2014 A little bit of ... sometimes the onset of irritability, sadness, or apathy can ... September 2014 Harvard Health Letter. , "Mood-related ... stresses. If they occur for long periods, cause significant ... to seek help," says Dr. Nancy Donovan, an instructor ...
(Date:9/2/2014)... Eric Jimenez and Leah Ashley announced ... revolutionary makeup application device. Designed to improve and accelerate ... the palm of women’s hands to help them get ... Me’s success lies in its patented technology. With a ... 15,000 pulses per minute, the device applies foundation evenly ...
(Date:9/2/2014)... B. E. Smith, the only full-service leadership solutions ... to lead a national chief executive officer ... Sioux Falls, S.D. The top executive search firm in ... more than 900 healthcare executives into organizations. , ... and nationally recognized leader in patient-centered care. It is ...
(Date:9/2/2014)... Syracuse, NY (PRWEB) September 02, 2014 ... A. Gadlage, M.D. & Associates in Duluth, GA and ... the EarQ team at the 2014 National ... in Cancun, Mexico. , While interacting with the former ... maintaining hearing health, the team provided free hearing screenings, ...
Breaking Medicine News(10 mins):Health News:HMHP Offers ‘Health at Home’ Workshop 2Health News:When a Mood Swing Signals Trouble, From the September 2014 Harvard Health Letter 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 2Health News:Color Me Launches With Ulta Beauty Revolutionary Makeup Application Device Gets Women Flawless in a Flash 3Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 3Health News:The EarQ Team Brings Hearing Health Awareness to the 2014 National Basketball Retired Players Association Annual Convention in Cancun 2
... a few glasses of wine enough to disrupt normal development, ... Just a few glasses of wine over a short period ... the Medical College of Georgia. , The initial signs ... include facial malformations such as a flat and high upper ...
... Benefit Muscular Dystrophy Research , ... Iselin, NJ (PRWEB) ... [Sanford-Brown Iselin] (SBI), in New Jersey, raised $11,000 for muscular ... the event are in support of local non-profit www.ryansquest.org ...
... to recent news,about Michigan,s first identified case of chronic ... issued the following statement., With hunting season fast ... a deer on a Kent County farm understandably has,created ... great state of Michigan. The deer farming industry in ...
... Surgery Seems to be the Provider of Choice for Recent,Big ... Next?, Months of constant cameras, mirrors all around and ... a major impact on how you feel,about the way you ... reality. Upon leaving the house contestants may undoubtedly spend,hours watching ...
... to $19 million, NATICK, Mass., Aug. 29 ... the U.S. District Court of,Marshall, Texas found two patents ... conduct during the prosecution of the patents,before the United ... previously found that certain Boston Scientific balloon,catheters and stent ...
... leadership and State delegations as a possible solution to national health ... ... 2008 -- If there has been any one consistent message offered ... the party platform initiative to resolve our national health care issues., ...
Cached Medicine News:Health News:Alcohol in Early Pregnancy May Prompt Fetal Cell Death 2Health News:Sanford-Brown Institute - Iselin Raises $11,000 for Ryan's Quest 2Health News:Deer Farm Industry in Michigan Issues Statement on the Recent Chronic Wasting Disease Case Identified on a Kent County Deer Farm 2Health News:MYA Makes Big Brother Stars Amazing! 2Health News:MYA Makes Big Brother Stars Amazing! 3Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3Health News:AMD Global Telemedicine Inc. Invited to Attend Democratic National Convention 2
...
The Tew cranial/spinal retractor is designed for posterior fossa or intraspinal microsurgery where retraction is required. Clinical applications are: Posterior fossa microsurgery and intraspinal micr...
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
The Budde Halo brain retractor is designed for use in all intercranial procedures where retraction of delicate brain tissue is required....
Medicine Products: